Actinobac Biomed is a spin-out from UMDNJ. Their focus is on development of pharmaceutical technologies based upon agents which target Leukocyte Function Antigen-1. The first targeted therapeutics is to treat hematologic malignancies such as leukemia, lymphoma, and myeloma.
In June 2011, Actinobac Biomed demonstrated in vivo efficacy for psoriasis treatment. Click here for more information.
Ascendia Pharmaceuticals LLC
Ascendia Pharmaceuticals LLC, founded in 2012, is a privately owned specialty pharmaceutical company, engaged in the research and development of innovative specialty pharmaceutical products, including enhanced formulation of existing medicine, niche hospital drugs in injectable pharmaceuticals, and pharmaceutical R&D development service, leveraging its proprietary drug delivery technologies including amorphous solid dispersion, injectable, and controlled release.
BioMed King Inc.
BioMed King Inc. focuses on biomarker R& D as well as biomarker assay development and testing for large pharmaceutical company projects. They can support the development of companion diagnostics from early biomarker discovery in the pre-clinical phase to the development and delivery of a diagnostic test. They plan to establish a CLIA (Clinical Laboratory Improvement Amendments) registered molecular clinical laboratory to offer centralized clinical biomarker testing for trial enrichment and/or personalized medicine.
Bionex's mission is to realize biopharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development to full-scale commercialization, in biopharmaceutical, food and cosmetic products. Second, Bionex develops and out-licenses its own proprietary formulations, technologies, and products related to drug, health food, and skin-care applications.
Biotecnol is a biopharmaceutical company focusing on the discovery, engineering and development of novel biopharmaceutical products. Most are multifunctional antibody molecules, directed to key therapeutic targets. Using its technologies, Biotecnol is developing a unique pipeline of products for applications in major disease areas. Enhancing antibodies efficacy by engineering multi-specificity via the creation of bi-specific antibody formats has emerged as a promising new wave in antibody.
Brighter Ideas, Inc.
Brighter Ideas (a Rutgers University spin out) is a biotechnology company focused on advancing fluorescent protein technology. The company offers unique high throughput screening (HTS) assays, protein purification kits, purified antibodies, and premium quality proteins. The company will focus on promoting its latest development which is a biomedical test for proteases and protease inhibitors called “GFP-on-a-string”.
Celvive, Inc. is a biotechnology company being spun out of UMDNJ-CINJ utilizing technology for the preparation of intrathecal administration of bone-marrow derived stem cells for neural regeneration in those incurring spinal cord injuries (SCI) from such events as motor vehicle accidents, falls, sports related injuries, and violence.
Conversion Energy Enterprises (CEE)
CEE is a privately-held corporation that was formed to develop and prototype innovative laser products for medical applications. CEE also provides consulting services to large and small business clients in optoelectronics, lasers, sensors and advanced electronics.
The company's focus is on utilization of a novel, proprietary, biocompatible, laser activated tissue adhesive that can be used as an alternative to sutures and staples with initial emphasis on hernia repair.
FluiDda Inc. is a spinoff company from the University of Antwerp whose main focus is developing imaging biomarkers to enhance drug development and patient care. These biomarkers combine biomedical imaging and advanced engineering methods resulting in a proprietary CT/CFD Pulmonary Imaging Technology that can be used as a diagnostic and research tool. The company technology has been validated in twenty clinical trials and has been focused on respiratory diseases such as asthma, COPD, and sleep apnea.
GeneAssess is a biotechnology company being spun out of UMDNJ .The company will pursue utilizing a cancer molecular signature (Fry) that they have primarily characterized in a breast cancer model. Their findings suggest that Fry could be used as a platform to develop cancer-gene based susceptibility tests, genetic and immunological companion diagnostics, as well the discovery of new drugs for aggressive and/or advanced breast cancer in particular.
Hudson BioPharma, Inc.
Hudson BioPharma Inc. has incorporated in New Jersey and was created to develop anti-cancer medicines through utilization of their proprietary technology in the design and synthesis of drug leads targeting protein-to-protein interaction. The primary focus of Hudson BioPharma will be on utilizing tumor protein P53 (a natural tumor suppressor that regulates cell division by keeping cells from growing and dividing too fast or in an uncontrolled way), to develop an anti-cancer medicine.
Hurel Corporation provides patented micro fluidic devices and cell culture that elevate the metabolic competency and endurance of cells cultured in vitro, and that simulate pharmacokinetic interactions among multiple tissues and organs. These proprietary capabilities produce unrivaled levels of physiologically relevant predictive sensitivity- “human relevance”- that define the current state of the art of hepatic and multi-tissue cell-based assays.
Ikaria, Inc. is fully integrated biotherapies company focused on developing and commercializing innovative therapeutics and interventions designed to meet the significant unmet needs of critically ill patients. Critical care medicine is the multi-disciplinary healthcare specialty focused on the care of patients with acute, life threatening illness or injury. Problems that might need critical care treatment may include complications from surgery, accidents, infections, critical organ failure and severe cardiopulmonary conditions.
Kamat Pharmatech, LLC
Kamat Pharmatech, LLC is a newly formed company that will operate as a contract research organization while developing its own technology focussing in the area of injectable products such as anti-inflammatory drugs that target autoimmune diseases.
Linnovision Inc. has developed the next generation of RFID (radio frequency identification) and will be applying it to the wearable health and fitness device market with emphasis on in-home monitoring, assisted living, hospitals, and clinics where information will be sent to various locations remotely. The new technology will not require batteries, will be more cost effective, and will allow for greater information transfer ultimately through use of smart phones.
Nanion Technologies is a spin-off company from the Center of Nanoscience (CeNS) of the University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.
Nexomics Biosciences, Inc.
Nexomics Biosciences, Inc. is a Rutgers spinout focusing on the discovery, development and commercialization of novel drugs for cancer, antiviral and antibiotic treatments. Additionally, Nexomics Biosciences functions as a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community.
NutraSorb, LLC pioneers the use of a proprietary, groundbreaking process that naturally concentrates the beneficial phytonutrients from fruits and vegetables into foods in amounts sufficient to promote health and wellness. The science-based, tasty, natural and shelf-stable functional foods and ingredients deliver an effective daily dose of antioxidants, polyphenols and other phytonutrients in a few servings, while reducing sugars and unwanted calories. NutrasorbTM technology is green and environmentally friendly, generating no waste or pollution. It was invented by leading researchers from major US universities, who joined forces to create a new generation of innovative, nutritional products for the benefit of humankind.
Orthobond is a privately held medical company developing surface modification technology that can be applied to virtually any synthetic material to produce a desired biological response. The Company’s covalently-bound-nano-technology withstands high sheer forces and repeated sterilization. Orthobond believes the technology will provide significant clinically measurable benefits for a wide array of implantable prostheses and diagnostic applications.
PCAsso is a research and development diagnostics company committed to the identification and development of novel medical diagnostic technologies.
PDS Biotechnology Corporation
PDS Biotechnology is harnessing the newly discovered properties of specific synthetic positively charged (cationic) lipids to develop a new generation of more versatile, simpler, safer and significantly more potent B- and T-cell activating vaccines. PDS’s proprietary Versamune™ platform nanotechnology when combined with T-cell antigens leads to superior cures for infection and cancer.
Shionogi Inc. is the U.S. based group company of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company. Shionogi Inc., develops and commercializes pharmaceutical products that address unmet medical needs. Together with their Japanese corporate parent, Shionogi has been providing innovative medicines essential to people’s health. Shionogi’s products in development seek to help patients with a variety of diseases and conditions, including male sexual health, pediatric conditions, women’s health, HIV, pain and diabetes. Shionogi has set up a non-GMP testing laboratory at CCIT to bring its product research work in-house.
SkinAxis, LLC is a biotechnology company providing unique research and development services for the pharmaceutical, biotechnology, chemical, and cosmetic industries involved with drug and active ingredient discovery. Their exclusive in-house technology provides important, reliable, and previously unobtainable data on human skin and lip responses for drug and active ingredient discovery.
TAXIS Pharmaceutical is focused on pharmaceutical discovery and development of antimicrobials targeting drug-resistant bacterial pathogens. They are currently in the process of commercializing a novel class of small-molecule compounds based on exclusive worldwide rights to the IP jointly owned by Rutgers and UMDNJ.
TRIM-edicine is a biotechnology company developing novel biopharmaceutical products designed to treat a number of unmet medical needs in areas such as oral care, dermal injuries, microsurgery, sports medicine, and muscular dystrophy. Their technology is based on a series of molecular, biochemical, and animal model studies which led to the discovery of a novel protein named mitsuggumin53 (MG53) which represents the first known molecular component that is essential for the intrinsic cellular membrane repair process. MG53 is expressed exclusively in skeletal and cardiac tissues and provides a unique target for therapeutic interventions in systemic diseases of heart failure, muscular dystrophy, stress associated muscle injury, and age-related muscular atrophy. In non-muscle cells, MG53 has been shown to enhance the membrane repair function of a number of tissues including epithelial cells; therefore, the potential use for UV exposure, wrinkles, wounds, or burns is a strong possibility.
TRIM-edicine's co-founder and chief scientific officer, Dr. Noah Weisleder, was awarded the prestigious 2011 Kauffman Foundation Outstanding Postdoctoral Entrepreneur Award. Click here for more information on this award.
Vasade Biosciences, Inc.
Vasade Bioscience Inc. is a growth-stage biotechnology company committed to the pre-clinical discovery and development of cardio protective and vascular protective molecules, drugs, and devices for the prevention, treatment, and management of cardiovascular disease, the leading cause of death worldwide. By combining its unique expertise in animal models of cardiovascular diseases with state-of-the-arts genetic, genomic, and proteomic technologies. Vasade has positioned itself in the development of novel cardiovascular therapeutic drugs for the treatment of cardiac hypertrophy, coronary artery disease, myocardial infarction, and heart failure. Their development pipeline focuses on the rational discovery, design, and development of small molecules, peptides, and gene therapies targeting novel cell-signaling molecules that influence cardiac cell growth and survival.
Viya Pharma, LLC
Viya Pharma LLC is a CRO focusing on new quantitative bioanalytical techniques using automated liquid handling in concert with HPLC and mass spectrometry technology to provide unique services to the life science industry. Their service platform is applicable to late stage drug discovery, PK studies, drug development, toxicity, enzyme profiling, and support of clinical trials.
Vyzin Inc. is a New Jersey based corporation and the creator of the mobile health brand VESAG. VESAG is a mobile based Personal Emergency Response System (MPERS) that provides proactive remote healthcare monitoring and recording of vital signs without the need to see a healthcare provider.
Vyzin has supplied innovative, environmental sound products to a rapidly changing marketplace. Working with their customers, they research, formulate and deliver the best solution at low cost and quick turnaround time. Vyzin is a proven innovator in the field of health care, electronics, telecommunications, information technology and manufacturing, with a passion for providing application specific solutions for their customers’ most difficult day to day business challenges.